DUPIXENT (Sanofi-Aventis Australia Pty Ltd)
Product name
DUPIXENT
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
158 working days (255)
Active ingredients
dupilumab
Registration type
EOI
Indication
Atopic Dermatitis
DUPIXENT (solution for injection) is now also indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.